develop
rna
interfer
rnai
technolog
util
short
interf
rna
sequenc
sirna
base
target
therapeut
focus
creat
method
deliv
sirna
cell
enhanc
sirna
stabil
vitro
vivo
describ
novel
approach
sirna
cellular
deliveri
use
sirna
encapsul
liposom
addit
bear
arginin
octam
molecul
attach
outer
surfac
human
doubl
minut
gene
sirna
demonstr
signific
stabil
degrad
blood
serum
sirnaload
remain
intact
even
incub
higher
transfect
effici
three
test
lung
tumor
cell
line
sirna
deliveri
success
proce
presenc
plasma
protein
demonstr
low
nonspecif
toxic
mechan
action
sirna
associ
rnaimedi
degrad
target
mrna
sirna
effect
inhibit
target
gene
significantli
reduc
prolifer
cancer
cell
approach
offer
potenti
sirna
deliveri
variou
vitro
vivo
applic
rnai
exploit
varieti
laboratori
applic
biolog
promis
therapeut
product
clinic
use
sirna
hinder
three
major
problem
rapid
enzymat
degrad
result
short
halflif
blood
poor
cellular
uptak
insuffici
tissu
bioavail
gener
problem
partli
overcom
mix
sirna
cation
lipid
cation
polym
form
complex
could
addit
surfacemodifi
specif
ligand
allow
target
requir
tissu
modifi
sirna
cellpenetr
peptid
cpp
success
appli
deliveri
variou
cargo
varieti
cell
vitro
vivo
howev
approach
frequent
fail
aggreg
sirnacarri
posit
charg
complex
blood
presenc
plasma
protein
result
unfavor
pharmacokinet
mainli
due
rapid
uptak
tissu
mononuclear
phagocyt
system
mp
lipoplex
also
known
cation
amphiphil
cation
liposom
develop
capabl
deliv
dna
rna
includ
plasmid
encod
sirna
sequenc
sirna
cellular
membran
achiev
high
activ
rnai
particular
frequent
use
deliveri
sirna
despit
certain
success
use
lipoplex
agent
allow
littl
control
process
interact
sirna
lead
final
product
sirnalipoplex
particl
excess
size
low
stabil
incomplet
encapsul
sirna
molecul
therebi
expos
sirna
potenti
enzymat
physic
degrad
prior
deliveri
cell
complex
sensit
toward
serum
therefor
optim
transfect
must
perform
use
serumfre
condit
obviou
shortcom
potenti
vivo
applic
addit
complex
work
effici
mani
cell
type
toxic
cell
experiment
anim
altern
approach
synthes
lipophil
deriv
sirna
coupl
hydrophob
moieti
cholesterol
significantli
improv
vitro
cellular
uptak
vivo
pharmacolog
properti
sirna
describ
develop
new
strategi
function
sirna
deliveri
cell
load
sirna
liposom
bear
arginin
octam
molecul
attach
liposom
surfac
belong
larg
group
socal
cellpenetr
peptid
cpp
posit
charg
enter
cell
ad
exogen
variou
cpp
success
use
deliveri
exogen
molecul
oligonucleotid
protein
even
small
particl
iron
oxid
nanoparticl
liposom
quantum
dot
cytoplasm
nuclei
cultur
cell
thu
dnaload
liposom
deliv
variou
cell
multipl
tat
peptid
molecul
attach
liposom
surfac
allow
success
transfect
tatliposomedna
complex
vitro
vivo
synthet
oligoarginin
shown
effect
cpp
allow
exampl
success
cell
transfect
plasmid
complex
hypothes
sirnaload
formul
use
charg
neutral
ratio
dotap
sirna
addit
poli
ethylen
glycol
phosphatidylethanolamin
pegp
conjug
increas
vivo
longev
provid
effect
transfect
system
vitro
vivo
egg
phosphatidylcholin
egg
pc
dotap
cholesterol
ch
dppe
methoxi
polyethyleneglycol
pegp
lissamin
rhodamin
blabel
glycerophosphoethanolamin
rhpe
avanti
polar
lipid
triethylamin
polyoxyethylen
mw
bi
pnitrophenyl
carbon
pnp
peg
sepharos
compon
buffer
solut
purchas
sigma
cell
cultur
media
fetal
bovin
serum
fb
gibco
invitrogen
water
deioniz
distil
solut
buffer
compon
made
analyt
grade
chemic
nt
sirna
chemic
synthes
acetoxythoxi
methyl
etherprotect
oligo
shanghai
genepharma
co
shanghai
china
synthet
oligonucleotid
deprotect
anneal
purifi
describ
manufactur
duplex
format
confirm
nondenatur
polyacrylamid
gel
electrophoresi
sirna
sampl
store
diethylpyrocarbon
depc
treat
water
sirna
sequenc
target
genbank
acc
correspond
code
region
start
codon
includ
sens
antisens
determin
uptak
effici
sirna
fluorescencelabel
sirna
synthes
coupl
fluorescein
isothiocyan
fitc
purchas
aldrich
sens
strand
use
mock
sirna
sequenc
polyarginin
peptid
synthes
use
solid
phase
techniqu
commerci
avail
fluorenylmethoxycarbonyl
fmoc
amino
acid
resin
reagent
pe
biosystem
ca
appli
biosystem
peptid
synthes
fmoc
chemistri
use
hexafluorphosph
hatu
coupl
reagent
peptid
cleav
resin
use
trifluoroacet
acid
triisopropyl
silan
phenol
h
subsequ
peptid
filter
resin
precipit
diethyl
ether
purifi
use
hplc
reversephas
column
alltech
altima
chicago
il
usa
character
use
matrixassist
laser
desorpt
mass
spectrometri
percept
biosystem
boston
usa
studi
arginin
octam
use
cellpenetr
peptid
sirna
deliveri
cell
pnppegp
synthes
accord
previous
report
method
chang
briefli
mg
dppe
dissolv
chloroform
obtain
mgml
solut
solut
supplement
ml
tea
two
gram
pnp
peg
dissolv
ml
chloroform
ad
mixtur
sampl
incub
overnight
room
temperatur
stir
argon
organ
solvent
remov
use
rotari
evapor
pnppegp
micel
form
hcl
use
water
bath
sonic
micel
separ
unbound
peg
releas
pnp
column
sepharos
use
hcl
eluent
pool
fraction
contain
pnppegp
freezedri
pnppegp
purifi
rphplc
prepar
column
use
methanol
hcl
vv
mobil
phase
fraction
contain
pnppegp
collect
mobil
phase
remov
use
vacuum
evapor
pnppegp
identifi
nmr
tlc
store
powder
coupl
pnppegp
perform
describ
modif
briefli
mg
pnppegp
first
dri
chloroform
solut
argon
overnight
incub
high
vacuum
result
film
hydrat
dispers
vortex
min
solut
hcl
molar
ratio
suspens
ml
tri
buffer
ph
ad
mix
incub
overnight
argon
atmospher
sinc
modifi
becom
amphiphil
form
micel
micel
separ
nonreact
free
overnight
dialysi
distil
water
use
spectrum
dialysi
bag
mwco
kda
sampl
freezedri
identifi
nmr
tlc
store
powder
dri
lipid
film
compos
egg
pc
ch
pegp
dotap
hydrat
sirna
aqueou
solut
sirna
use
quantiti
suffici
neutral
posit
charg
dotap
mixtur
first
heat
min
cool
room
temperatur
transfer
onto
dri
film
form
dri
conjug
methanol
system
incub
incub
anoth
h
molar
fraction
conjug
total
lipid
quantifi
liposomeincorpor
fluoresc
intens
determin
lyse
liposom
sd
measur
fluoresc
intens
ex
nm
em
nm
sinc
initi
quantiti
phospholipid
alway
known
well
number
phospholipid
molecul
form
liposom
given
size
could
estim
exact
quantiti
given
associ
singl
liposom
incorpor
rang
molecul
per
liposom
diamet
nm
liposom
dispers
cryofix
plung
liquid
ethan
cool
liquid
nitrogen
freezefractur
replica
prepar
use
balzer
baf
freezeetch
system
replica
neg
stain
uranyl
acet
examin
jeol
cx
electron
microscop
particl
size
surfac
charg
determin
zetas
malvern
instrument
malvern
uk
estim
sirna
encapsul
effici
liposom
examin
sirna
serum
stabil
sampl
sirna
fitclabel
sirna
either
aqueou
solut
differ
liposom
prepar
incub
alon
mix
ratio
fresh
mous
serum
give
serum
concentr
aliquot
sampl
taken
differ
incub
time
load
onto
gel
electrophoresi
perform
visual
intact
sirna
enter
gel
run
clearli
visibl
band
stain
ethidium
bromid
lung
squamou
cell
carcinoma
nonsmal
cell
lung
carcinoma
small
cell
lung
carcinoma
cell
line
purchas
american
type
cultur
collect
atcc
manassa
va
cell
cultur
eagl
minim
essenti
medium
cell
cell
cultur
supplement
fb
mm
sodium
pyruv
lglutamin
maintain
co
humidifi
atmospher
intracellular
traffick
local
test
vitro
three
chosen
human
lung
cancer
cell
line
seed
dish
glass
cover
slip
bottom
mattek
corpor
ashland
cell
grown
confluenc
incub
rhpelabel
plain
liposom
fb
medium
h
thirti
minut
prior
visual
cell
incub
hoechst
solut
pb
cell
wash
three
time
steril
pb
mount
pb
cover
cover
slip
seal
nail
polish
live
cell
directli
analyz
leica
tcssp
confoc
laser
scan
microscop
equip
argon
krypton
hene
laser
laser
power
photomultipli
set
kept
ident
sampl
make
result
compar
test
whether
peptid
abl
deliv
sirnacontain
liposom
three
differ
human
lung
cancer
cell
line
cell
seed
dish
glass
cover
slip
bottom
grown
confluenc
treat
fitcsirnacontain
plain
liposom
quantiti
requir
deliv
rna
per
cell
sirna
concentr
ad
liposom
suspens
serumfre
fb
fb
fb
fb
media
h
cell
studi
confoc
microscopi
describ
cell
treat
differ
concentr
h
h
adher
float
cell
collect
ptpcr
western
blot
analysi
perform
western
blot
centrifug
lysat
protein
sampl
analyz
sdspolyacrylamid
gel
electrophoresi
transfer
polyvinyliden
difluorid
pvdf
membran
semidri
transfer
membran
block
h
room
temperatur
trisbuff
salin
contain
tween
bsa
blot
probe
follow
primari
monoclon
antibodi
overnight
antibodi
santa
cruz
biotechnolog
inc
santa
cruz
ca
usa
follow
incub
appropri
horseradish
peroxidaseconjug
secondari
antibodi
dilut
h
detect
achiev
enhanc
chemiluminesc
amersham
pharmacia
biotech
expos
film
filter
quantit
scan
total
rna
prepar
cultur
cell
transfect
differ
concentr
h
ptpcr
carri
use
onestep
rtpcr
kit
invitrogen
catalogu
oligonucleotid
primer
use
follow
forward
revers
forward
revers
mrna
use
intern
control
amplif
product
resolv
agaros
gel
electrophoresi
visual
ethidium
bromid
stain
cell
seed
tissu
cultur
microtit
plate
h
cultur
medium
remov
cell
treat
sirna
sirna
fb
medium
experi
carri
without
sirna
sever
differ
concentr
provid
sirna
concentr
nm
h
andor
h
celltit
aqueou
one
solut
promega
ad
well
plate
incub
h
assay
base
bioreduct
compound
mt
color
solubl
formazan
product
viabil
cell
measur
use
plate
reader
thermo
germani
nm
rel
viabil
calcul
cell
treat
medium
alon
control
statist
analysi
data
perform
accord
student
ttest
two
popul
develop
simpl
method
produc
sirnacontain
method
involv
hydrat
dri
lipid
film
compos
mol
egg
pc
mol
ch
mol
pegp
mol
dotap
depctreat
aqueou
solut
sirna
sirna
concentr
chosen
neutral
posit
charg
dotap
zeta
potenti
final
prepar
around
zero
sirnacontain
liposom
incub
conjug
pnppegp
final
formul
contain
steric
protect
layer
peg
expos
moieti
cellpenetr
peptid
allow
effici
deliveri
liposom
sirna
cell
see
relat
scheme
fig
zeta
potenti
valu
liposom
prepar
measur
use
zetas
demonstr
liposom
without
attach
liposom
molar
ratio
attach
posit
zeta
potenti
respect
quantiti
sirna
encapsul
liposom
prepar
zeta
potenti
liposom
without
attach
around
zero
liposom
attach
insignific
increas
zeta
potenti
valu
structur
prepar
made
character
freezefractur
neg
stain
electron
microscopi
em
particl
appear
nearli
round
numer
tini
spheric
format
tightli
adher
form
mosaic
pattern
particl
surfac
format
size
around
nm
fig
crossfractur
particl
reveal
particl
hollow
similar
organ
outer
inner
side
fig
particl
size
rang
nm
result
consist
data
obtain
use
dynam
light
scatter
analysi
fig
shape
size
result
particl
also
confirm
neg
stain
em
data
shown
interestingli
structur
sirnacontain
resembl
structur
sar
coronaviru
although
relev
signific
find
remain
unclear
molecul
sirna
locat
insid
small
particl
hollow
core
lager
particl
address
question
gelelectrophoresi
use
determin
trace
sirna
two
differ
dispers
prepar
quantiti
sirna
lipid
one
prepar
obtain
describ
obtain
mix
preform
cation
sirna
aqueou
solut
term
complex
sampl
contain
quantiti
sirna
load
onto
gel
electrophoresi
perform
visual
sirna
band
stain
ethidium
bromid
fig
case
sirna
releas
free
form
result
band
intens
close
controlfre
sirna
fig
compar
lane
band
much
lower
intens
compar
control
free
sirna
seen
howev
treatment
prepar
sodium
dodecyl
sulfat
sd
min
two
sirna
band
seen
intens
markedli
brighter
lyse
fig
compar
lane
one
band
close
load
posit
much
lower
intens
compar
anoth
one
intens
posit
close
control
free
sirna
addit
sirna
prepar
stain
ethidium
bromid
suggest
sirna
molecul
tightli
coat
lipid
membran
base
previou
data
inform
present
propos
follow
mechan
assembl
fig
posit
charg
dri
lipid
film
hydrat
aqueou
solut
contain
nt
short
doublestrand
strongli
neg
charg
rna
two
type
differ
forc
act
within
system
electrostat
interact
sirna
cation
polar
head
dotap
drive
format
invert
hexagon
structur
entrap
singl
sirna
molecul
hydrophob
interact
lipid
result
format
bilay
liposom
membran
pegp
prevent
vesicl
aggreg
heat
system
induc
rearrang
lipid
molecul
membran
cover
surfac
small
invert
hexagon
micel
arrang
form
larger
mosaic
vesicl
theoret
calcul
support
model
nt
sirna
consid
rigid
rod
diamet
length
thick
lipid
bilay
egg
pc
vesicl
nm
vari
acyl
chain
length
freezefractur
em
show
small
vesicl
diamet
nm
diamet
indic
small
vesicl
repres
singl
sirna
molecul
coat
singl
lipid
bilay
sinc
exonucleolyt
degrad
main
mechan
sirna
degrad
serum
investig
whether
sirna
structur
protect
degrad
result
demonstr
incub
free
sirna
fitclabel
sirna
serum
result
degrad
h
sirna
fulli
degrad
fig
b
pictur
incub
serum
variou
time
interv
control
band
seen
fig
lysi
sd
howev
load
sirna
releas
liposom
band
seen
intens
close
control
free
sirna
except
mobil
band
slower
free
sirna
fig
fact
sirna
releas
sd
slower
mobil
free
sirna
could
explain
possibl
interact
sd
serum
compon
sirna
releas
size
exclus
electrostat
interact
main
factor
retard
mobil
releas
sirna
sirna
encapsul
show
high
stabil
serum
remain
intact
even
incub
time
tradit
cation
lipoplex
dotap
protect
sirna
serummedi
degrad
longer
time
yield
product
littl
stabl
nake
sirna
notic
presenc
sirna
degrad
product
fig
f
possibl
sirna
condens
complex
form
dotap
remain
expos
degrad
complex
subject
electrophoresi
sirna
releas
free
form
result
band
intens
close
control
free
sirna
fig
compar
lane
test
transloc
effici
depend
cellular
uptak
distribut
time
temperatur
liposom
without
label
rhpe
process
uptak
distribut
visual
confoc
microscopi
three
lung
cancer
cell
line
uptak
distribut
similar
cell
type
fig
typic
pattern
timedepend
transloc
shown
cell
shown
fig
cell
nuclei
stain
blue
hoechst
h
overlay
show
evid
coloc
label
rhpe
hoechst
indic
accumul
predominantli
cell
membran
andor
cytoplasm
time
similar
tatliposom
gradual
migrat
closer
nuclei
h
signific
fraction
seen
within
perinuclear
region
fig
virtual
uptak
liposom
without
cell
type
even
upon
incub
long
h
data
shown
effect
temperatur
uptak
process
examin
follow
incub
fluoresc
label
cell
variou
time
shown
fig
fluoresc
observ
plasma
membran
cell
time
fluoresc
intens
increas
still
remain
accumul
plasma
membran
data
suggest
liposom
uptak
cell
proce
via
activ
temperaturedepend
mechan
rather
direct
penetr
across
plasma
membran
cell
sirna
deliv
differ
type
cell
address
question
label
fitc
observ
transloc
sirna
confoc
microscopi
experi
compar
transfect
efficaci
liposom
without
attach
demonstr
effici
transfect
three
type
cell
even
incub
short
h
fig
liposom
without
modif
virtual
ineffect
deliveri
sirna
three
type
cell
even
prolong
incub
h
fluoresc
observ
sampl
fig
effect
local
fitcsirna
assess
h
transfect
sirnaassoci
fluoresc
observ
cytoplasm
nuclei
test
serum
effect
transloc
cell
variou
concentr
fb
use
cultur
medium
shown
fig
treatment
even
serum
demonstr
substanti
higher
fluoresc
compar
low
serumcontain
medium
fb
result
slight
decreas
fluoresc
intens
cell
treat
howev
increas
fb
concentr
medium
caus
signific
decreas
deliveri
primari
measur
effect
silenc
target
mrna
result
correspond
reduct
protein
level
test
silenc
mrna
use
rtpcr
method
determin
cell
shown
fig
level
markedli
downregul
cell
transfect
dosedepend
manner
h
western
blot
use
examin
effect
treatment
level
protein
shown
fig
transfect
sirna
direct
result
signific
decreas
protein
level
dosedepend
manner
h
contrast
express
neither
protein
chang
cell
treat
use
differ
concentr
nm
variou
time
h
h
data
shown
result
suggest
could
provid
novel
effect
way
enhanc
transfect
effici
sirna
presenc
serum
mt
method
use
examin
possibl
cytotox
cell
incub
lipid
kill
cell
quantiti
use
comparison
kill
cell
fig
upon
extend
incub
h
show
high
toxic
cell
surviv
rate
lipid
concentr
contrast
lipid
concentr
h
cell
viabl
fig
result
show
use
concentr
nontox
even
incub
effect
growth
inhibit
cell
also
investig
comparison
cell
treat
variou
concentr
sirna
h
sirna
inhibit
growth
tumor
cell
even
nm
sirna
fig
howev
tumor
cell
treat
nm
sirna
demonstr
signific
tumor
cell
growth
inhibit
cell
viabil
vs
presenc
concentr
empti
fig
toxic
observ
cell
treat
nake
even
concentr
high
nm
result
clearli
confirm
therapeut
activ
sirna
significantli
enhanc
use
nontox
serumresist
load
demonstr
high
stabil
protect
incorpor
sirna
degrad
blood
serum
even
incub
system
allow
high
transfect
effici
three
type
test
lung
tumor
cell
transfect
take
place
even
presenc
plasma
protein
addit
system
low
cytotox
stabl
upon
storag
less
releas
sirna
month
data
shown
gel
electrophoresi
demonstr
electrophoret
behavior
significantli
differ
free
sirna
fig
much
lower
intens
compar
free
sirna
lyse
howev
sd
lyse
two
sirna
band
seen
intens
markedli
brighter
lyse
fig
indic
case
load
sirna
releas
free
form
new
band
close
load
posit
higher
molecular
weight
free
sirna
lesser
neg
charg
free
sirna
could
reflect
complex
sirna
dotap
molecul
form
result
noncomplet
liposom
degrad
sd
even
tripl
complex
neg
charg
sirna
sd
dotap
sinc
neg
charg
sd
form
complex
cation
lipid
dotap
aqueou
solut
lipid
composit
size
distribut
surfac
charg
liposom
easili
manipul
provid
clinic
accept
formul
system
deliveri
process
format
liposom
sirna
react
head
group
liposom
dotap
form
neutral
coordin
complex
result
minim
charg
reduct
membran
surfac
charg
essenti
improv
stabil
sirnalipid
formul
blood
stream
decreas
uptak
reticuloendotheli
system
studi
confirm
mechan
action
sirna
determin
rnaimedi
degrad
target
mrna
show
biolog
activ
cell
demonstr
advantag
encapsul
sirna
major
limit
lipid
formul
sirna
use
far
appear
excess
posit
charg
limit
specif
cell
type
result
unwant
tissu
distribut
high
toxic
vivo
use
sirna
carrier
expect
overcom
problem
achiev
three
major
goal
reduct
system
toxic
enhanc
stabil
circul
time
sirna
prepar
blood
stream
increas
sirna
permeat
cell
methodolog
may
also
prove
use
encapsul
deliveri
oligonucleotid
sirna
repres
novel
nonvir
prepar
appli
rnai
techniqu
compar
nonvir
vector
provid
effici
silenc
target
gene
great
reduct
toxic
high
stabil
serum
